Dong-A ST Co Ltd
KRX:170900
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Dong-A ST Co Ltd
Total Equity
Dong-A ST Co Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Dong-A ST Co Ltd
KRX:170900
|
Total Equity
₩642.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
|
Yuhan Corp
KRX:000100
|
Total Equity
₩2.3T
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Total Equity
₩813B
|
CAGR 3-Years
37%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Total Equity
₩1.2T
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
6%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Total Equity
₩276B
|
CAGR 3-Years
17%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Total Equity
₩212.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
Dong-A ST Co Ltd
Glance View
Dong-A ST Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Seoul, Seoul. The company went IPO on 2013-04-08. The firm is involved of the manufacturing and sale of gastric mucosal protective agents, antihistamines, ischemic modifiers, antithrombotic agents, functional dyspepsia, hyperlipidemia, growth hormone, peptic ulcer treatments, cerebral metabolism improvement and hypertension treatments. The company produces and sells diagnostic reagents for hepatitis E, I, A and B. In addition, it is engaged in the production and sale of medical devices including implants for artificial joint and maxillofacial surgery. The firm distributes its products in domestic and overseas markets such as Brazil, Turkey and Cambodia.
See Also
What is Dong-A ST Co Ltd's Total Equity?
Total Equity
642.7B
KRW
Based on the financial report for Dec 31, 2025, Dong-A ST Co Ltd's Total Equity amounts to 642.7B KRW.
What is Dong-A ST Co Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
2%
Over the last year, the Total Equity growth was -4%. The average annual Total Equity growth rates for Dong-A ST Co Ltd have been -1% over the past three years , and 2% over the past ten years .
